Navigation Links
INC Research and invivodata Announce ePRO Partnership

invivodata’s Regulatory Expertise Enhances CRO's Robust Global Service Offering

Raleigh, NC and Pittsburgh, PA (Vocus) March 4, 2010 -- INC Research®, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results and invivodata®, inc., the industry leader in patient reported outcomes (PRO) solutions and services for global clinical research, today announced a partnership in which invivodata provides its ePRO solutions and services as a component of INC’s full service offering portfolio. The partnership has evolved from the successful execution of multiple international clinical trials in which INC Research and invivodata clinical service teams have delivered ePRO solutions and services to global biopharmaceutical customers.

INC Research has unrivaled expertise and a reputation for conducting global clinical development programs of the highest integrity. With its focus on providing its customers fit for purpose solutions, INC Research continually assesses industry developments to adopt proven technologies into their complete range of customized clinical trial services.

“We chose to partner with invivodata based on the integration of scientific and regulatory principles into their ePRO solution - elements critical in ensuring high patient compliance and reliable data,” said Alistair Macdonald, INC Research’s executive vice president, Strategic Development. “By leveraging our relationship with invivodata, we can continue to guide our customers through any regulatory changes that may affect their research decisions, especially in light of the recent publication of the FDA's final PRO Guidance.”

invivodata combines scientific and regulatory expertise with practical technology and proactive services that enable clinical trial sponsors to confidently determine the effectiveness of new medical products and therapies. invivodata scientists and regulatory experts have long contributed to industry meetings that helped shape PRO guidance and have provided expertise to clinical researchers making key decisions about their PRO strategies for global clinical development programs.

"Having collaborated on multiple international clinical trials to date, invivodata and INC Research have developed synergies between our teams that drive real-world efficiencies in clinical research and better equip our customers to manage their clinical development processes," said Doug Engfer, invivodata president and CEO. “We’re eager to continue building on our long-term relationship with INC Research, and to help maximize the value they deliver to global biopharmaceutical organizations.”

About invivodata inc.
invivodata combines behavioral science, information technology, and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata’s electronic Patient Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata’s solutions include comprehensive trial-support services that facilitate the collection of ePRO data, web-based access to study data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consulting on the use of PRO data in a regulated environment. invivodata’s solution has been used in more than 275 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information visit

About INC Research® Inc.
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women’s health trials. The company’s The Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit

# # #

Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. New Research Reveals Mechanism By Which TNFerade(TM) Suppresses Metastases
2. Sorting device for analyzing biological reactions puts the power of a lab in a researchers pocket
3. U.S. Government Awards DuPont, Partners with Technology Investment Agreement for Macroalgae-to-Biobutanol Research
4. New Source for Science Funding: BenchFly Pioneers Search for Research Program
5. Stem Cell Innovations to Provide Research and Assay Services to Agennix.
6. Sunlight Research(TM), Releases its Osiris Therapeutics Stem Cell Patent Report
7. No New Findings in Atrazine Study Promoted by Discredited Researcher, According to the Hudson Institute Center for Global Food Issues
8. Funds Boost Research into Causes, Interventions for Age-Related Cognitive Decline
9. Stephen Coles is Recognized by Continental Whos Who Among Health Care Research Professionals
10. febits miRBase 14 Geniom-Biochip Now With 58 Additional New Sequences Available for Cancer Research
11. Researchers gain detailed insight into failing heart cells using new nano technique
Post Your Comments:
Related Image:
INC Research and invivodata Announce ePRO Partnership
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
Breaking Biology Technology:
(Date:10/29/2015)... JOLLA, Calif. , Oct. 29, 2015  The ... a new report titled, "DNA Synthesis and Biosecurity: Lessons ... well the Department of Health and Human Services guidance ... issued in 2010. --> ... but it also has the potential to pose unique ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
(Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
Breaking Biology News(10 mins):